Inceptor Bio Announces $37 Million Series A Financing

Inceptor Bio, a biotechnology company advancing cell therapies for difficult-to-treat cancers, has announced the closing of a $37 million Series A financing led by Kineticos Ventures.

Proceeds from the Series A financing will be used to advance Inceptor Bio’s CAR-T lead program to a Phase I clinical trial and continue development of its CAR-M and CAR-NK platforms. Additionally, proceeds will support completion of Inceptor Bio’s Advanced Manufacturing Platform (AMP+) facility, a 29,000 square foot, state-of-the-art cell and gene therapy GMP manufacturing site located in Gainesville, Florida.

Inceptor Bio’s CAR-T, CAR-M, and CAR-NK platforms are at the center of a diversified portfolio of cell therapies focused on novel mechanisms that enhance cell performance in the tumor microenvironment. Novel technologies include a co-stimulatory domain M83, proprietary TMax manufacturing process, the K62 platform, which increases the phagocytic capabilities of macrophages and supports a M1 anti-tumor phenotype, and a differentiated iPSC technology.

“We are grateful for the continued support of Kineticos Ventures and our life sciences investors,” said Shailesh Maingi, Founder and CEO of Inceptor Bio. “We have a simple strategy at Inceptor Bio. We’re advancing novel CAR-T, CAR-M and CAR-NK platforms into the clinic, securing our supply through AMP+, and building a leading team of scientists and engineers in order to improve treatment options for patients with difficult-to-cancers.”

“This Series A funding allows us to focus on advancing our lead CAR-T program into the clinic while continuing to advance our other exciting cell therapy platforms,” said Mike Nicholson, Ph.D., President and Chief Operating Officer of Inceptor Bio. “Our programs address serious challenges in the cell therapy arena, and fully realizing the potential of these therapies requires significant capital. We are grateful for the support of this incredible group of investors.”

“Investing in early life sciences companies with promising pipelines like Inceptor Bio is at the heart of what we do,” said Frank Lis, President of Kineticos Ventures. “With an expert team and a scalable manufacturing facility, Inceptor Bio is well positioned to advance next-generation cell therapy technologies to address difficult-to-treat cancers.”

Related posts